Skip to content

Artivion AORT Repayments of Short-Term Debt

Repayments of Short-Term Debt at other companies

Boston Scientific logo
Boston ScientificBSX
$259M-76.1%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$3.22B+52.0%

Other financials

Income statement

See full
Revenue$116.3M+17.5%
Gross profit$75.4M+18.7%
Operating income$5.8M+170%
Net income$1.4M+381%
EPS (diluted)$0.03+400%

Balance sheet

See full
Cash & equivalents$55.8M+47.9%
Total debt$258.2M-28.8%
Total equity$450.5M+53.1%
Total assets$883.2M+11.6%

Cash flow

See full
Operating cash flow$1.2M+107%
CapEx$8.0M+120%
Free cash flow-$6.8M+66.7%

Valuation

See full
Market cap$1.07B-22.7%
Enterprise value$1.27B-25.5%
P/E91.5×
P/S2.3×-1.2×

Profitability

See full
Gross margin64.6%+0.6pp
Operating margin8.2%+4.1pp
Net margin2.5%+1.5pp
FCF margin-0.1%-2.5pp

Returns & leverage

See full
Return on equity3.1%+1.8pp
Debt / equity0.6×-0.7×
Current ratio3.9×-1.7×

Where this comes from

Reported directly by Artivion in its filing.

Tagged under the XBRL concept us-gaap:RepaymentsOfShortTermDebt.

The official record: Artivion’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Artivion's repayments of short-term debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Artivion's repayments of short-term debt?
Artivion (AORT) reported repayments of short-term debt of $577K in Q1 2026.
What is the long-term trend for Artivion's repayments of short-term debt?
Over 3 years (2021 to 2025), Artivion's repayments of short-term debt has grown at a 96.0% compound annual growth rate (CAGR), from $299K to $2.25M.